Roivant Discovery Inc. has disclosed PROTACs (proteolysis targeting chimeras) comprising an E3 ubiquitin ligase binding moiety covalently linked to an E3 ubiquitin-protein ligase Mdm2 (Hdm2)-targeting moiety through a linker.
Scientists at the Institute of Cancer Research have generated a proteolysis targeting chimera (PROTAC) that successfully destroyed RIPK1 in cancer cells.
Shanghai- and San Diego-based Degron Therapeutics Inc. secured a potential $1.2 billion deal with Tokyo-headquartered Takeda Pharmaceutical Co. Ltd. May 23 for a multitarget collaboration and exclusive licensing agreement for molecular glue degraders. “It is a breakthrough technology in the small-molecule drug discovery field,” Degron CEO Lily Zou told BioWorld. “People talk about cell and gene therapy, but small molecules are still the mainstream of drug discovery, [with] more reach.”
Shanghai- and San Diego-based Degron Therapeutics Inc. secured a potential $1.2 billion deal with Tokyo-headquartered Takeda Pharmaceutical Co. Ltd. May 23 for a multitarget collaboration and exclusive licensing agreement for molecular glue degraders. “It is a breakthrough technology in the small-molecule drug discovery field,” Degron CEO Lily Zou told BioWorld. “People talk about cell and gene therapy, but small molecules are still the mainstream of drug discovery, [with] more reach.”
Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Tocris Cookson Ltd., Helmholtz Zentrum fur Infektionsforschung GmbH and University of Lübeck have described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands covalently bonded to non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) targeting moiety through linker reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Suzhou, China-based Kintor Pharmaceutical Ltd. reported positive findings from a phase II study of GT-20029, a topical therapy for male androgenetic alopecia, on April 21 – boosting both the company’s stock and its chances of a late-stage clinical study in China and the U.S.
Suzhou, China-based Kintor Pharmaceutical Ltd. reported positive findings from a phase II study of GT-20029, a topical therapy for male androgenetic alopecia, on April 21 – boosting both the company’s stock and its chances of a late-stage clinical study in China and the U.S.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) has divulged protein cereblon (CRBN) ligands and its PROTACs reported to be useful for the treatment of cancer.
